These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 16362459

  • 1. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
    Padagas J, Colloton M, Shalhoub V, Kostenuik P, Morony S, Munyakazi L, Guo M, Gianneschi D, Shatzen E, Geng Z, Tan HL, Dunstan C, Lacey D, Martin D.
    Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM, Pearse RN.
    Cancer; 2003 Feb 01; 97(3 Suppl):802-12. PubMed ID: 12548579
    [Abstract] [Full Text] [Related]

  • 4. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De la Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez-Rodríguez Mde L.
    Alcohol Alcohol; 2006 Feb 01; 41(3):261-6. PubMed ID: 16476762
    [Abstract] [Full Text] [Related]

  • 5. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
    Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET.
    Cancer Res; 2003 Nov 15; 63(22):7883-90. PubMed ID: 14633717
    [Abstract] [Full Text] [Related]

  • 6. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H.
    J Hepatol; 2005 Dec 15; 43(6):973-83. PubMed ID: 16143421
    [Abstract] [Full Text] [Related]

  • 7. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G.
    Steroids; 2005 Dec 01; 70(13):847-55. PubMed ID: 16005483
    [Abstract] [Full Text] [Related]

  • 8. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
    Schett G, Middleton S, Bolon B, Stolina M, Brown H, Zhu L, Pretorius J, Zack DJ, Kostenuik P, Feige U.
    Arthritis Rheum; 2005 May 01; 52(5):1604-11. PubMed ID: 15880601
    [Abstract] [Full Text] [Related]

  • 9. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
    Humphrey EL, Williams JH, Davie MW, Marshall MJ.
    Bone; 2006 May 01; 38(5):652-61. PubMed ID: 16298558
    [Abstract] [Full Text] [Related]

  • 10. Plasma osteoprotegerin is associated with mortality in hemodialysis patients.
    Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM.
    J Am Soc Nephrol; 2006 Jan 01; 17(1):262-70. PubMed ID: 16280472
    [Abstract] [Full Text] [Related]

  • 11. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM, Croucher PI.
    Cancer Res; 2003 Mar 01; 63(5):912-6. PubMed ID: 12615702
    [Abstract] [Full Text] [Related]

  • 12. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E, Orive A, García-Unzueta M, Amado JA, Casafont F, Pons-Romero F.
    Clin Transplant; 2006 Mar 01; 20(3):383-8. PubMed ID: 16824158
    [Abstract] [Full Text] [Related]

  • 13. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK, Chen YL, Chang HC, Li CL, Kuo MY.
    J Periodontal Res; 2006 Aug 01; 41(4):354-60. PubMed ID: 16827732
    [Abstract] [Full Text] [Related]

  • 14. Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin.
    Bock O, Loch G, Schade U, Büsche G, Wasielewski R, Wiese B, Kreipe H.
    Br J Haematol; 2005 Jul 01; 130(1):76-82. PubMed ID: 15982347
    [Abstract] [Full Text] [Related]

  • 15. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
    Kostenuik PJ, Bolon B, Morony S, Daris M, Geng Z, Carter C, Sheng J.
    Bone; 2004 Apr 01; 34(4):656-64. PubMed ID: 15050896
    [Abstract] [Full Text] [Related]

  • 16. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
    Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.
    Biochem Biophys Res Commun; 2006 Aug 25; 347(2):460-7. PubMed ID: 16828054
    [Abstract] [Full Text] [Related]

  • 17. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
    Maïmoun L, Couret I, Mariano-Goulart D, Dupuy AM, Micallef JP, Peruchon E, Ohanna F, Cristol JP, Rossi M, Leroux JL.
    Calcif Tissue Int; 2005 Jun 25; 76(6):404-11. PubMed ID: 15812577
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.